Grant: Master's Award: Canada Graduate Scholarships
Université de Montréal
$17,500.00
G protein couple receptor for a targeted therapy of T-cell acute lymphoblastic leukemia
EF 2014-15
Résumé
Acute lymphoblastic leukemia (ALL) is the most common type of childhood cancer, and T-ALL represents 20 % of those, with a peak at 2-5 years of age. Although this neoplastic disorder originates in the thymus, leukemic cells spread throughout the whole body and the disease is rapidly fatal without therapy. Current treatments of T-ALL achieve good survival rates of more than 80% in children but with severe side effects. Furthermore, about 50% of adolescents and 60% of adults succumb to T-ALL. Therefore, innovative strategies are needed to further improve survival and reduce adverse effects. The search for molecular drug targets and the design of tumour-specific therapy is therefore the main goal of current research efforts in Dr Hoang`s laboratory. Using a large scale screening technology, recent work in the laboratory identified new compounds that specifically inhibit the aberrant self-renewal activity induced by oncogenes in leukemic stem cells. In this project, I propose to identify how newly identified compounds that act on G protein coupled receptor (GPCR) can inhibit the growth of these leukemic stem cells,
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
331548
Name
Picard Louis-Philippe
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
G protein couple receptor for a targeted therapy of T-cell acute lymphoblastic leukemia
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Therapy; Cell Signaling; G Proteins Couple Receptor; Leukemia; Leukemic Stem Cells; T-Cell Acute Lymphoblastic Leukemia; Targeted Therapy
Abstract
Acute lymphoblastic leukemia (ALL) is the most common type of childhood cancer, and T-ALL represents 20 % of those, with a peak at 2-5 years of age. Although this neoplastic disorder originates in the thymus, leukemic cells spread throughout the whole body and the disease is rapidly fatal without therapy. Current treatments of T-ALL achieve good survival rates of more than 80% in children but with severe side effects. Furthermore, about 50% of adolescents and 60% of adults succumb to T-ALL. Therefore, innovative strategies are needed to further improve survival and reduce adverse effects. The search for molecular drug targets and the design of tumour-specific therapy is therefore the main goal of current research efforts in Dr Hoang`s laboratory. Using a large scale screening technology, recent work in the laboratory identified new compounds that specifically inhibit the aberrant self-renewal activity induced by oncogenes in leukemic stem cells. In this project, I propose to identify how newly identified compounds that act on G protein coupled receptor (GPCR) can inhibit the growth of these leukemic stem cells,
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Picard, Louis-Philippe
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~